Cathay Biotech Inc
688065.SS · Process Industries · Chemicals: Major Diversified · CN
2,324 employees · cathaybiotech.com
About
Cathay Biotech Inc. generates revenue through the research and development, production, and sales of new bio-based materials. The firm's primary offerings include biological long-chain dibasic acids and bio-based polyamide series, such as lauric acid and brazilian acid. These products serve various industrial applications, including long-chain polyamides, fragrances, hot melt adhesives, lubricants, and powder coatings. The company distributes its products to both domestic and overseas markets. This global reach allows Cathay Biotech Inc. to capture value from a broad customer base across different regions. The business model relies on the continuous development and commercialization of these specialized bio-based chemical solutions.
Annual results
Reported figures, CNY · revenue up 11.4% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 3.3B | 565M | 17.1% | — |
| 2024 | 3.0B | 488M | 16.5% | — |
| 2023 | 2.1B | 366M | 17.3% | — |
| 2022 | 2.4B | 553M | 22.7% | — |
| 2021 | 2.4B | 594M | 25.1% | — |
Dividends per share
688065.SS in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Cathay Biotech Inc are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.